Navamedic ASA provided revenue guidance for the first half of 2022. The company has decided to provide a trading update based on estimated organic revenue growth for the first half of 2022 in excess of 30%. The high revenue growth is a result of a strong June 2022 and is driven by significant demand for Mysimba as well as other key products in the portfolio.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
34 NOK | -0.87% |
|
-0.87% | -7.36% |
25/06 | Orion Obtains License to Market Navamedic's Parkinson's Disease Drug in Europe | MT |
24/06 | Navamedic ASA and Orion Corporation Sign License & Supply Agreement for Flexilev in Europe | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.36% | 56.37M | |
+55.19% | 815B | |
+45.68% | 654B | |
-6.09% | 354B | |
+21.92% | 337B | |
+19.49% | 247B | |
+3.84% | 229B | |
+14.01% | 219B | |
+10.86% | 171B | |
-2.78% | 159B |
- Stock Market
- Equities
- NAVA Stock
- News Navamedic ASA
- Navamedic ASA Provides Revenue Guidance for the First Half of 2022